India's Alembic Pharma slips after US FDA warning letter

Alembic Pharmaceuticals

14/07/2026 05:37

** Shares of India's Alembic Pharmaceuticals ALEM.NS fall 1.2% to 821.15 rupees

        ** Stock on track to fall for second straight session
** Drugmaker says U.S. Food and Drug Administration issued warning letter to the clinical investigator associated with a bioequivalence study conducted at its Vadodara facility
** Adds letter relates to observations on the informed consent form used in study and does not concern data integrity
** Co says preliminary assessment indicates no restrictions on operations at bioequivalence facility
** Stock rated "buy" on average by 9 analysts; median PT is 900 rupees - LSEG-compiled data
** Stock down 2.7% in year through previous close

     

 (Reporting by Payel Das in Bengaluru)
 ((Payel.das@thomsonreuters.com))